FBLN2 promoter hypermethylation: a negative prognostic biomarker and anti-PD-1 response predictor in clear cell renal cell carcinoma via high-throughput CpG Island screening
FBLN2 promoter hypermethylation is a promising prognostic biomarker in ccRCC and a potential predictor of immunotherapy response. These findings warrant further investigation to validate its potential for enhancing personalized patient management.
Authors
- Guanhua Li (ORCID: https://orcid.org/0000-0002-8250-0628)
- Shuya Zhao
- Lufang Zhang (ORCID: https://orcid.org/0009-0004-0324-6644)
- Yueguo Li (ORCID: https://orcid.org/0000-0002-6462-9401)
- Jia Li (ORCID: https://orcid.org/0000-0002-1353-7347)
- Dong Dong (ORCID: https://orcid.org/0000-0001-9784-6472)
- Yawei Han
- Lianzi Yu
- Aimin Zhang (ORCID: https://orcid.org/0000-0002-5311-7021)
- Jie Shao (ORCID: https://orcid.org/0000-0002-4884-462X)
- Xin Yao (ORCID: https://orcid.org/0000-0002-1301-3631)
- Wenfeng Liao
- Jialei Hua
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- National Clinical Research (US)
- Chinese People's Liberation Army (CN)
- Aviation General Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1186/s13148-025-01981-2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Tianjin City
- Tianjin Medical University
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences